Literature DB >> 22156595

Mannose-binding lectin-associated serine protease-1 is a significant contributor to coagulation in a murine model of occlusive thrombosis.

Laura R La Bonte1, Vasile I Pavlov, Ying S Tan, Kazue Takahashi, Minoru Takahashi, Nirmal K Banda, Chenhui Zou, Teizo Fujita, Gregory L Stahl.   

Abstract

Bleeding disorders and thrombotic complications constitute a major cause of death and disability worldwide. Although it is known that the complement and coagulation systems interact, no studies have investigated the specific role or mechanisms of lectin-mediated coagulation in vivo. FeCl(3) treatment resulted in intra-arterial occlusive thrombogenesis within 10 min in wild-type (WT) and C2/factor B-null mice. In contrast, mannose-binding lectin (MBL)-null and MBL-associated serine protease (MASP)-1/-3 knockout (KO) mice had significantly decreased FeCl(3)-induced thrombogenesis. Reconstitution with recombinant human (rh) MBL restored FeCl(3)-induced thrombogenesis in MBL-null mice to levels comparable to WT mice, suggesting a significant role of the MBL/MASP complex for in vivo coagulation. Additionally, whole blood aggregation demonstrated increased MBL/MASP complex-dependent platelet aggregation. In vitro, MBL/MASP complexes were captured on mannan-coated plates, and cleavage of a chromogenic thrombin substrate (S2238) was measured. We observed no significant differences in S2238 cleavage between WT, C2/factor B-null, MBL-A(-/-), or MBL-C(-/-) sera; however, MBL-null or MASP-1/-3 KO mouse sera demonstrated significantly decreased S2238 cleavage. rhMBL alone failed to cleave S2238, but cleavage was restored when rMASP-1 was added to either MASP-1/-3 KO sera or rhMBL. Taken together, these findings indicate that MBL/MASP complexes, and specifically MASP-1, play a key role in thrombus formation in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22156595      PMCID: PMC3253146          DOI: 10.4049/jimmunol.1102916

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

1.  Association of mannose-binding-lectin deficiency with severe atherosclerosis.

Authors:  H O Madsen; V Videm; A Svejgaard; J L Svennevig; P Garred
Journal:  Lancet       Date:  1998-09-19       Impact factor: 79.321

2.  Complement mediates attenuation of endothelium-dependent relaxations in canine coronary arteries after porcine serum exposure: a mechanism for vascular thrombosis in xenograft hyperacute rejection.

Authors:  D G Cable; K Hisamochi; H V Schaff
Journal:  Circulation       Date:  1997-11-04       Impact factor: 29.690

3.  A truncated form of mannose-binding lectin-associated serine protease (MASP)-2 expressed by alternative polyadenylation is a component of the lectin complement pathway.

Authors:  M Takahashi; Y Endo; T Fujita; M Matsushita
Journal:  Int Immunol       Date:  1999-05       Impact factor: 4.823

4.  Differential effects of alpha- and gamma-tocopherol on low-density lipoprotein oxidation, superoxide activity, platelet aggregation and arterial thrombogenesis.

Authors:  T Saldeen; D Li; J L Mehta
Journal:  J Am Coll Cardiol       Date:  1999-10       Impact factor: 24.094

5.  A targeted disruption of the murine complement factor B gene resulting in loss of expression of three genes in close proximity, factor B, C2, and D17H6S45.

Authors:  P R Taylor; J T Nash; E Theodoridis; A E Bygrave; M J Walport; M Botto
Journal:  J Biol Chem       Date:  1998-01-16       Impact factor: 5.157

6.  Molecular basis of opsonic defect in immunodeficient children.

Authors:  M Sumiya; M Super; P Tabona; R J Levinsky; T Arai; M W Turner; J A Summerfield
Journal:  Lancet       Date:  1991-06-29       Impact factor: 79.321

7.  An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis research.

Authors:  Xinkang Wang; Lin Xu
Journal:  Thromb Res       Date:  2005       Impact factor: 3.944

8.  Complement activation in patients with acute myocardial infarction treated with streptokinase.

Authors:  S Oren; I Maslovsky; M Schlesinger; L Reisin
Journal:  Am J Med Sci       Date:  1998-01       Impact factor: 2.378

9.  Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice.

Authors:  P M Farrehi; C K Ozaki; P Carmeliet; W P Fay
Journal:  Circulation       Date:  1998-03-17       Impact factor: 29.690

10.  Heparin reversal by protamine in humans--complement, prostaglandins, blood cells, and hemodynamics.

Authors:  J Hobbhahn; P F Conzen; H Habazettl; R Gutmann; W Kellermann; K Peter
Journal:  J Appl Physiol (1985)       Date:  1991-10
View more
  35 in total

Review 1.  Complement activation, regulation, and molecular basis for complement-related diseases.

Authors:  Goran Bajic; Søren E Degn; Steffen Thiel; Gregers R Andersen
Journal:  EMBO J       Date:  2015-10-21       Impact factor: 11.598

2.  Association between endogenous complement inhibitor and myocardial salvage in patients with myocardial infarction.

Authors:  Charlotte B Holt; Steffen Thiel; Kim Munk; Jakob A Østergaard; Hans E Bøtker; Troels K Hansen
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2013-09-30

Review 3.  Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology.

Authors:  Masashi Mizuno; Yasuhiro Suzuki; Yasuhiko Ito
Journal:  Clin Exp Nephrol       Date:  2017-03-24       Impact factor: 2.801

4.  Elevated Serum Mannose-Binding Lectin Levels Are Associated with Poor Outcome After Acute Ischemic Stroke in Patients with Type 2 Diabetes.

Authors:  Fang-Yu Song; Meng-Hai Wu; Li-Hua Zhu; Zhi-Qiang Zhang; Qin-De Qi; Chang-Li Lou
Journal:  Mol Neurobiol       Date:  2014-10-25       Impact factor: 5.590

5.  Polyphosphate suppresses complement via the terminal pathway.

Authors:  Jovian M Wat; Jonathan H Foley; Michael J Krisinger; Linnette Mae Ocariza; Victor Lei; Gregory A Wasney; Emilie Lameignere; Natalie C Strynadka; Stephanie A Smith; James H Morrissey; Edward M Conway
Journal:  Blood       Date:  2013-12-13       Impact factor: 22.113

6.  Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development.

Authors:  Saravanan Subramaniam; Kerstin Jurk; Lukas Hobohm; Sven Jäckel; Mona Saffarzadeh; Kathrin Schwierczek; Philip Wenzel; Florian Langer; Christoph Reinhardt; Wolfram Ruf
Journal:  Blood       Date:  2017-02-21       Impact factor: 22.113

7.  Endogenous and natural complement inhibitor attenuates myocardial injury and arterial thrombogenesis.

Authors:  Vasile I Pavlov; Mikkel-Ole Skjoedt; Ying Siow Tan; Anne Rosbjerg; Peter Garred; Gregory L Stahl
Journal:  Circulation       Date:  2012-10-02       Impact factor: 29.690

8.  Human mannose-binding lectin inhibitor prevents myocardial injury and arterial thrombogenesis in a novel animal model.

Authors:  Vasile I Pavlov; Ying S Tan; Erin E McClure; Laura R La Bonte; Chenhui Zou; William B Gorsuch; Gregory L Stahl
Journal:  Am J Pathol       Date:  2014-12-04       Impact factor: 4.307

9.  Plasma levels of mannan-binding lectin (MBL)-associated serine proteases (MASPs) and MBL-associated protein in cardio- and cerebrovascular diseases.

Authors:  V Frauenknecht; S Thiel; L Storm; N Meier; M Arnold; J-P Schmid; H Saner; V Schroeder
Journal:  Clin Exp Immunol       Date:  2013-07       Impact factor: 4.330

10.  Elevated plasma CL-K1 level is associated with a risk of developing disseminated intravascular coagulation (DIC).

Authors:  Kazue Takahashi; Katsuki Ohtani; Mykol Larvie; Patience Moyo; Lorencia Chigweshe; Elizabeth M Van Cott; Nobutaka Wakamiya
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.